Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Biology

Cancer Oncology

Medicine

Internal Medicine

Electrical And Electronic Engineering

Show all topics

DOI

10.1016/s1470-2045(21)00375-2